PharmaShots Weekly Snapshots (January 01 – January 05, 2023)


This week PharmaShots’ news was all about the updates on M&A, Pharma, Clinical Trials, Regulatory & MedTech. Check out our full report below:

 For an Aggregate of $295M, Roche to Acquire LumiraDx’s Point of Care Technology

Read More: LumiraDx                                                                                                                             

For an Aggregate of ~$185M, Tome Biosciences to Acquire Replace Therapeutics

Read More: Tome Biosciences                                                                                                                

HR Pharmaceuticals and Poiesis Medical Sign a Commercialization Agreement for Dual Balloon Catheter Technology in North America

Read More: HR Pharmaceuticals & Poiesis Medical                                                                           

ANGLE Signs a Contract with Eisai for the Pilot Study Worth $250,000

Read More: ANGLE& Eisai                                                                                                                     

Voyager Therapeutics and Novartis Sign a Collaboration and License Agreement to Advance Novel Gene Therapies for Huntington’s Disease (HD) and Spinal Muscular Atrophy (SMA)

Read More: Voyager Therapeutics and Novartis                                                                      

MediLink Therapeutics and Roche Sign a Collaboration and License Agreement to Develop and Commercialize YL211 for Solid Tumors

Read More: MediLink Therapeutics & 

Coherus BioSciences Highlights the Availability of Loqtorzi (toripalimab-tpzi) for the Treatment of Nasopharyngeal Carcinoma (NPC) in the United States

Read More: Coherus BioSciences                                                                                                         

Elektrofi Signs a Collaboration and License Agreement with Janssen Biotech to Develop Five Programs for Oncology

Read More: Elektrofi                                                                                                                              

Boehringer Ingelheim Joins Forces with Riboure Pharmaceuticals to Develop RNAi Based Therapies for the Treatment of Liver Diseases 

Read More: Boehringer Ingelheim& Riboure Pharmaceuticals                                                               

AbbVie Partners with Umoja Biopharma to Develop CAR-T Cell Therapies for Hematologic Malignancies

Read More: AbbVie& Umoja Biopharma                                                                                            

Merck KGaA Signs a Collaboration Agreement with Inspira for the Development and Commercialization of Ompenaclid (RGX-202) to Treat Colorectal Cancer

Read More: Merck& Inspira                                                                                                                     

The US FDA Imposes Hold on Iovance Biotherapeutics’ Clinical Trial of LN-145 for Non-Small Cell Lung Cancer (NSCLC)

Read More: Iovance Biotherapeutics                                                                                                 

Stuart Therapeutics has Reported First Patient, First Visit in the P-III Study of Vezocolmitide for Dry Eye Disease

Read More: Stuart Therapeutics                                                                                                             

Innovent Doses First Patient in the P-III (GLORY-2) Trial of Mazdutide (IBI362) in Chinese Adults with Obesity

Read More:  Innovent                                                                                                                              

Longboard Pharmaceuticals Highlights the P-Ib/IIa Results for Bexicaserin (LP352) in Developmental and Epileptic Encephalopathies (DEEs)

Read More:  Longboard Pharmaceuticals                                                                                            

Agios Pharmaceuticals Highlights the P-III Results for Pyrukynd (mitapivat) to Treat Non-Transfusion-Dependent Alpha- or Beta-Thalassemia

Read More: Agios Pharmaceuticals                                                                                                 

Sitryx Therapeutics’s Partner Eli Lilly Initiates the P-I Study of SIT-011 to Treat Chronic Autoimmune and Inflammatory Diseases

Read More: Sitryx Therapeutics       

Lyndra Therapeutics highlight the P-III Results for Risperidone (LYN-005) to Treat Schizophrenia        Read More: Lyndra Therapeutics                    

Tryp Therapeutics Doses First Patient with TRP-8802 in P-IIa Clinical Trial for the Treatment of Fibromyalgia           

Read More: Tryp Therapeutics                                



NeuroBo Pharmaceuticals has Submitted IND Application to the US FDA for Conducting P-I Study of DA-1726 to Treat Obesity

Read More : NeuroBo                                                                                                                             

Zevra Therapeutics Reports Resubmission of Arimoclomol’s NDA to the US FDA for Treating Niemann-Pick disease Type C (NPC)

Read More: Zevra Therapeutics                                                                                                           

Silo Pharma and Sever Pharma Reports Regulatory Approval to Conduct the Development of   Ketamine Implant for Fibromyalgia

Read More: Silo Pharma & Sever Pharma                                                                                              

The US FDA Grants aNDA Approval to Loteprednol Etabonate Ophthalmic Suspension

Read More:  Lupin                                                                                                                              

AstraZeneca and Sanofi’s Beyfortus Receives NMPA’s Approval for the Prevention of Respiratory Syncytial Virus (RSV) Disease in Infants 

Read More: AstraZeneca                                                                                                                

The Clinical Hold Placed by the US FDA on Innate Pharma’s Clinical Evaluation of Lacutamab to Treat Sezary Syndrome is Lifted

Read More: Innate Pharma                                                                                                              

Health Canada Approves Pfizer’s Beqvez (fidanacogene elaparvovec) for the Treatment of Hemophilia B

Read More: Pfizer                                                                                                                              

The US FDA Approved AnX Robotica’s ProScan as an AI Assisted Reading Tool for Small Bowel Video Capsule Endoscopy

Read More: AnX                                                                                                                              

Alex Therapeutics Highlights the Clinical Trial Results for Almee to Treat Anxiety Associated with Pulmonary Fibrosis (PF)

Read More: Alex Therapeutics                                                                                                                

Glenmark has Launched Lirafit (Biosimilar, Liraglutide) in India for Type 2 Diabetes Mellitus

Read More: Glenmark                                                                                                                             

Microbot Medical Reports GLP Pivotal Pre-Clinical Study Results in Porcine Model

Read More: Microbot                                                                                                                              



Source link

Leave A Reply

Your email address will not be published.